Identifying genetic loci associated with antidepressant drug response with drug-gene interaction models in a population-based study

Journal of Psychiatric Research

Volumn 62, Issue , 2015, Pages 31-37

  Noordam, Raymond ^a   Direk, Nese ^a   Sitlani, Colleen M ^b   Aarts, Nikkie ^a   Tiemeier, Henning ^a   Hofman, Albert ^a,g   Uitterlinden, André G ^a,g   Psaty, Bruce M ^c,d   Stricker, Bruno H ^a,e,g   Visser, Loes E ^a,f  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d CENTER FOR HEALTH STUDIES   (United States)

^e HAGA ^*  (Netherlands)

^f Apotheek Haagse Ziekenhuizen   (Netherlands)

^g Netherlands Genomics Initiative   (Netherlands)

Author keywords

Drug response biomarkers; Gene environment interaction; Genome wide association study; Pharmacogenetics; Serotonin uptake inhibitors

Indexed keywords

SEROTONIN UPTAKE INHIBITOR; ANTIDEPRESSANT AGENT;

AGED; ARTICLE; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DEPRESSION; DRUG EXPOSURE; DRUG GENE INTERACTION; DRUG RESPONSE; FEMALE; FSHR GENE; GENE; GENE FREQUENCY; GENE IDENTIFICATION; GENE INTERACTION; GENE LOCUS; GENETIC ASSOCIATION; GENOTYPE; HMGB4 GENE; HTR2A GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HEALTH CARE PLANNING; META ANALYSIS (TOPIC); MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; COHORT STUDIES; COMMUNITY HEALTH PLANNING; CROSS-SECTIONAL STUDIES; DEPRESSION; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES;

EID: 84924324541     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2015.01.005     Document Type: Article

References (41)

1. Arias B., Fabbri C., Gressier F., Serretti A., Mitjans M., Gasto C., et al. TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression. Neuropsychobiology 2013, 67:41-47.
2. Athanasiou M, Holick K, Reed C, Salisbury B, Serretti A, Zou W. Patent: genetic markers associated with reponse to antidepressants (US 20090233942 A1). 2009.
3. Avery C.L., Der J.S., Whitsel E.A., Sturmer T. Comparison of study designs used to detect and characterize pharmacogenomic interactions in nonexperimental studies: a simulation study. Pharmacogenet Genomics 2014, 24:146-155.
4. Avery C.L., Sitlani C.M., Arking D.E., Arnett D.K., Bis J.C., Boerwinkle E., et al. Drug-gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval. Pharmacogenomics J 2013.
5. Beekman A.T., Deeg D.J., Van Limbeek J., Braam A.W., De Vries M.Z., Van Tilburg W. Criterion validity of the Center for Epidemiologic Studies Depression scale (CES-D): results from a community-based sample of older subjects in The Netherlands. Psychol Med 1997, 27:231-235.
6. Choi M.J., Kang R.H., Ham B.J., Jeong H.Y., Lee M.S. Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram. Neuropsychobiology 2005, 52:155-162.
7. de Bakker P.I., Ferreira M.A., Jia X., Neale B.M., Raychaudhuri S., Voight B.F. Practical aspects of imputation-driven meta-analysis of genome-wide association studies. Hum Mol Genet 2008, 17:R122-R128.
8. Franchini L., Serretti A., Gasperini M., Smeraldi E. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. JPsychiatr Res 1998, 32:255-259.
9. Garriock H.A., Kraft J.B., Shyn S.I., Peters E.J., Yokoyama J.S., Jenkins G.D., et al. Agenomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 2010, 67:133-138.
10. Gendep Investigators, Mars Investigators, Star D. Investigators Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry 2013, 170:207-217.
11. Hanley J.A., Negassa A., Edwardes M.D., Forrester J.E. Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol 2003, 157:364-375.
12. Hek K., Demirkan A., Lahti J., Terracciano A., Teumer A., Cornelis M.C., et al. Agenome-wide association study of depressive symptoms. Biol Psychiatry 2013, 73:667-678.
13. Hofman A., Darwish Murad S., van Duijn C.M., Franco O.H., Goedegebure A., Ikram M.A., et al. The Rotterdam Study: 2014 objectives and design update. Eur J Epidemiol 2013, 28:889-926.
14. Hofman A., Grobbee D.E., de Jong P.T., van den Ouweland F.A. Determinants of disease and disability in the elderly: the Rotterdam elderly Study. Eur J Epidemiol 1991, 7:403-422.
15. Horstmann S., Binder E.B. Pharmacogenomics of antidepressant drugs. Pharmacol Ther 2009, 124:57-73.
16. International HapMap C. The international HapMap project. Nature 2003, 426:789-796.
17. Ising M., Lucae S., Binder E.B., Bettecken T., Uhr M., Ripke S., et al. Agenomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 2009, 66:966-975.
18. Kato M., Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010, 15:473-500.
19. Laje G., McMahon F.J. Genome-wide association studies of antidepressant outcome: a brief review. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1553-1557.
20. Lipsitz S.R., Fitzmaurice G.M., Orav E.J., Laird N.M. Performance of generalized estimating equations in practical situations. Biometrics 1994, 50:270-278.
21. Lister A., Regan C., Van Zwol J., Van Der Kraak G. Inhibition of egg production in zebrafish by fluoxetine and municipal effluents: a mechanistic evaluation. Aquat Toxicol 2009, 95:320-329.
22. Lucae S., Ising M., Horstmann S., Baune B.T., Arolt V., Muller-Myhsok B., et al. HTR2A gene variation is involved in antidepressant treatment response. Eur Neuropsychopharmacol 2010, 20:65-68.
23. Malki K., Uher R., Paya-Cano J., Binder E., Rietschel M., Zobel A., et al. Convergent animal and human evidence suggests a role of PPM1A gene in response to antidepressants. Biol Psychiatry 2011, 69:360-365.
24. McMahon F.J., Buervenich S., Charney D., Lipsky R., Rush A.J., Wilson A.F., et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006, 78:804-814.
25. O'Reilly R.L., Bogue L., Singh S.M. Pharmacogenetic response to antidepressants in a multicase family with affective disorder. Biol Psychiatry 1994, 36:467-471.
26. Pan W., Wall M.M. Small-sample adjustments in using the sandwich variance estimator in generalized estimating equations. Stat Med 2002, 21:1429-1441.
27. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007, 81:559-575.
28. Radloff L.S. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977, 1:385-401.
29. Richards J.B., Rivadeneira F., Inouye M., Pastinen T.M., Soranzo N., Wilson S.G., et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet 2008, 371:1505-1512.
30. Sangkuhl K., Klein T.E., Altman R.B. Selective serotonin reuptake inhibitors pathway. Pharmacogenet Genomics 2009, 19:907-909.
31. Satterthwaite F.E. An approximate distribution of estimates of variance components. Biometrics 1946, 2:110-114.
32. Sitlani C.M., Rice K.M., Lumley T., McKnight B., Cupples L.A., Avery C.L., et al. Generalized estimating equations for genome-wide association studies using longitudinal phenotype data. Stat Med 2014.
33. Tansey K.E., Guipponi M., Hu X., Domenici E., Lewis G., Malafosse A., et al. Contribution of common genetic variants to antidepressant response. Biol Psychiatry 2013, 73:679-682.
34. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163:28-40.
35. Uher R., Perroud N., Ng M.Y., Hauser J., Henigsberg N., Maier W., et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 2010, 167:555-564.
36. Wang H.C., Yeh T.L., Chang H.H., Gean P.W., Chi M.H., Yang Y.K., et al. TPH1 is associated with major depressive disorder but not with SSRI/SNRI response in Taiwanese patients. Psychopharmacol Berl 2011, 213:773-779.
37. Willer C.J., Li Y., Abecasis G.R. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 2010, 26:2190-2191.
38. Yan T., Wang L., Kuang W., Xu J., Li S., Chen J., et al. Brain-derived neurotrophic factor Val66Met polymorphism association with antidepressant efficacy: a systematic review and meta-analysis. Asia-Pacific Psychiatry: Off J Pac Rim Coll Psychiatrists 2014, 6:241-251.
39. Zeger S.L., Liang K.Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986, 42:121-130.
40. Zhao X., Huang Y., Li J., Ma H., Jin Q., Wang Y., et al. Association between the 5-HT1A receptor gene polymorphism (rs6295) and antidepressants: a meta-analysis. Int Clin Psychopharmacol 2012, 27:314-320.
41. Zou Y.F., Wang Y., Liu P., Feng X.L., Wang B.Y., Zang T.H., et al. Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients. Neuropsychobiology 2010, 61:71-78.